AR075798A1 - Proteinas de union a il-17 (interleuquina 17) - Google Patents

Proteinas de union a il-17 (interleuquina 17)

Info

Publication number
AR075798A1
AR075798A1 ARP100100680A ARP100100680A AR075798A1 AR 075798 A1 AR075798 A1 AR 075798A1 AR P100100680 A ARP100100680 A AR P100100680A AR P100100680 A ARP100100680 A AR P100100680A AR 075798 A1 AR075798 A1 AR 075798A1
Authority
AR
Argentina
Prior art keywords
present
cdr
seq
proteins
interleuquina
Prior art date
Application number
ARP100100680A
Other languages
English (en)
Inventor
Chung-Ming Hsieh
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42710240&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR075798(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of AR075798A1 publication Critical patent/AR075798A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)

Abstract

Proteínas de union a IL-17 y/o IL-17F, su uso en composiciones y métodos para el tratamiento, prevencion, y diagnostico de enfermedades relacionadas con IL-17 y para detectar IL-17 en células, tejidos, muestras y composiciones. Reivindicacion 1: Una proteína de union que comprende un dominio de union al antígeno capaz de unir IL-17 humana, caracterizada porque dicho dominio de union al antígeno comprende al menos una CDR que comprende una secuencia de aminoácidos seleccionada del grupo formado por: CDR-H 1. X1-X2-X3-X4-X5 (SEQ ID Ns:919), en donde; X1 es D o S; X2 es Y; X3 es E o G; X4.es l, M, V, o F; X5 es H; CDR-H2. X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-X16-X17 (SEQ ID Ns:920), en donde; X1 es V; X2 es T, 1, o N; X3 es D, H, o W; X4 es P o no está presente; X5 es E, G, o S; X6 es S, N, o D; X7 es G; X8 es G o T, X9 es T; X10 es L, A, T, o F; X11 es H o Y; X12 es N; X13 es P, Q, o S; X14 es K, A, o N; X15 es F o L; X16 es D, K, o R; y X17 es G, D, o S; CDR-H3. X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12 (SEQ ID Ns:921), en donde; X1 es Y, F, o D; X2 es Y, L, S, o G; X3 es K, T, R, o Y; X4 es Y o W; X5 es E, D, o I; X6 es S, G, o Y; X7 es F, Y, o T; X8 es Y, F, o M; X9 es G, T, o no está presente; X10 es M o no está presente; X11 es D; y X12 es Y; CDR-L1. X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-X16 (SEQ ID Ns:922), en donde; X1 es S, K, o R; X2 es A o S; X3 es S; X4 es S o Q; X5 es S o no está presente; X6 es L o no está presente; X7 es V o no está presente; X8 es H o no está presente; X9 es S o no está presente; X10 es S, N, o no está presente; X11 es S, V, o G; X12 es I, N, o S; X13 es S, N, T, o I; X14 es Y o D; X15 es M, V, L, o I; y X16 es C, A, H, Y, o G; CDR-L2. X1-X2-X3-X4-X5-X6-X7 (SEQ ID Ns:923), en donde; X1 es D, Y, K, A, o H; X2 es T, A, o V; X3 es S o F; X4 es K, N, o E; X5 es L o R; X6 es A, Y, o F; y X7 es S o T; y CDR-L3. X1-X2-X3-X4-X5-X6-X7-X8-X9 (SEQ ID Ns:924), en donde; X1 es Q, S, o H; X2 es Q; X3 es R, D, S, o G; X4 es S, Y, o T; X5 es S, G, o H; X6 es Y, S, V, o A; X7 es P o no está presente; X8 es W, Y, o L; y X9 es T.
ARP100100680A 2009-03-05 2010-03-05 Proteinas de union a il-17 (interleuquina 17) AR075798A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20927209P 2009-03-05 2009-03-05

Publications (1)

Publication Number Publication Date
AR075798A1 true AR075798A1 (es) 2011-04-27

Family

ID=42710240

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100100680A AR075798A1 (es) 2009-03-05 2010-03-05 Proteinas de union a il-17 (interleuquina 17)

Country Status (24)

Country Link
US (7) US8835610B2 (es)
EP (4) EP3235509A1 (es)
JP (3) JP5836807B2 (es)
KR (2) KR101579771B1 (es)
CN (2) CN102781470B (es)
AR (1) AR075798A1 (es)
BR (1) BRPI1013688A8 (es)
CA (1) CA2752648A1 (es)
CL (2) CL2011002129A1 (es)
CO (1) CO6410314A2 (es)
CR (1) CR20110470A (es)
DO (1) DOP2011000274A (es)
EC (1) ECSP11011297A (es)
HK (2) HK1200320A1 (es)
IL (1) IL214851A0 (es)
MX (1) MX2011009362A (es)
NZ (2) NZ611324A (es)
PE (3) PE20160651A1 (es)
PH (1) PH12015500093A1 (es)
RU (2) RU2015132478A (es)
SG (2) SG173705A1 (es)
TW (2) TW201613969A (es)
UY (1) UY32477A (es)
WO (1) WO2010102251A2 (es)

Families Citing this family (166)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ544317A (en) 2003-07-08 2009-05-31 Genentech Inc IL-17 A/F heterologous polypeptides and therapeutic uses thereof
EP2009101B1 (en) 2006-03-31 2017-10-25 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
JP5646457B2 (ja) 2008-04-29 2014-12-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
EP3002299A1 (en) * 2008-06-03 2016-04-06 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
KR20110016959A (ko) 2008-06-03 2011-02-18 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
AU2009268585C1 (en) 2008-07-08 2014-10-02 Abbvie Inc. Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
RU2015132478A (ru) 2009-03-05 2015-12-10 Эббви Инк. Связывающие il-17 белки
MX348013B (es) 2009-05-05 2017-05-23 Novimmune Sa Anticuerpos anti il-17f y metodos de uso de los mismos.
RU2570639C2 (ru) 2009-08-29 2015-12-10 Эббви Инк Терапевтические dll4-связывающие белки
RU2012112550A (ru) * 2009-09-01 2013-10-10 Эбботт Лэборетриз Иммуноглобулины с двумя вариабельными доменами и их применение
BR112012008833A2 (pt) * 2009-10-15 2015-09-08 Abbott Lab imunoglobulinas de dominio variavel duplo e usos das mesmas
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
AU2011223919B2 (en) 2010-03-02 2015-03-19 Abbvie Inc. Therapeutic DLL4 binding proteins
KR20130010123A (ko) 2010-04-07 2013-01-25 아비에 인코포레이티드 ＴＮＦ-α 결합 단백질
BR122014011544A2 (pt) 2010-05-14 2019-08-13 Abbvie Inc proteínas de ligação à il-1
CN102906118B (zh) 2010-05-20 2017-07-28 埃博灵克斯股份有限公司 与her3相关的生物材料
MY160445A (en) * 2010-08-03 2017-03-15 Abbvie Inc Dual Variable Domain Immunoglobulins And Uses Thereof
RU2013113225A (ru) 2010-08-26 2014-10-10 Эббви Инк. Иммуноглобулины с двумя вариабельными доменами и их применение
CA2813466A1 (en) 2010-10-01 2012-04-05 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids that disrupt major groove binding partner interactions
KR20140008305A (ko) 2010-11-05 2014-01-21 노파르티스 아게 Ｉｌ-１７ 길항제를 사용한 류마티스성 관절염의 치료 방법
KR20240025059A (ko) 2010-11-30 2024-02-26 추가이 세이야쿠 가부시키가이샤 세포상해 유도 치료제
WO2012088290A2 (en) * 2010-12-22 2012-06-28 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
US20120201746A1 (en) * 2010-12-22 2012-08-09 Abbott Laboratories Half immunoglobulin binding proteins and uses thereof
WO2012094300A2 (en) * 2011-01-04 2012-07-12 The United States of America, as represented by the Secretary, Department of Health and Human Services Office of Technology Transfer National Institutes of Health Methods of treating age-related macular degeneration
DK2663579T3 (en) 2011-01-14 2017-07-31 Univ California THERAPEUTIC ANTIBODIES AGAINST ROR-1 PROTEIN AND PROCEDURES FOR USE THEREOF
WO2012099886A1 (en) 2011-01-18 2012-07-26 Bioniz, Llc Compositions and mehthods for modulating gamma-c-cytokine activity
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201112429D0 (en) * 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
MX2014004981A (es) 2011-10-24 2014-09-11 Abbvie Inc Inmunoaglutinantes dirigidos contra tnf.
MX2014004980A (es) * 2011-10-24 2014-09-11 Abbvie Inc Inmunoaglutinantes biespecificos dirigidos contra tnf e il-17.
CN104203978A (zh) 2011-10-24 2014-12-10 艾伯维股份有限公司 针对硬化蛋白的免疫结合剂
EP2787078B1 (en) 2011-10-31 2019-05-22 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain
US9198900B2 (en) 2011-11-10 2015-12-01 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Treatment of peritoneal injury using JAK inhibitors
EP2597102A1 (en) 2011-11-25 2013-05-29 Covagen AG A novel fusion protein comprising an antibody light chain and a polypeptide binding to IL-17
JP2015508994A (ja) * 2011-12-30 2015-03-26 アッヴィ・インコーポレイテッド Ｉｌ−１３および／またはｉｌ−１７に対する二重可変ドメイン免疫グロブリン
MX2014009490A (es) 2012-02-10 2014-08-29 Novo Nordisk As Metodos relacionados con el tratamiento de enfermedades y trastornos inflamatorios.
EA201401077A1 (ru) * 2012-04-05 2015-02-27 Ф.Хоффманн-Ля Рош Аг Биспецифические антитела к человеческому tweak и человеческому il17 и их применения
WO2013164440A1 (en) 2012-05-03 2013-11-07 Novo Nordisk A/S Methods related to treatment of inflammatory diseases and disorders
EP2852615B1 (en) 2012-05-22 2018-12-05 Bristol-Myers Squibb Company Il-17a/f il-23 bispecific antibodies and their uses
EP2711016A1 (en) 2012-09-21 2014-03-26 Covagen AG Novel IL-17A binding molecules and medical uses thereof
US9217042B2 (en) * 2012-10-23 2015-12-22 Abbott Cardiovascular Systems Inc. Method of reducing MACE in diabetic patients subsequent to stent placement
EP2911664B1 (en) 2012-10-25 2019-05-08 The General Hospital Corporation Combination therapies for the treatment of alzheimer's disease and related disorders
KR20190096459A (ko) 2012-11-01 2019-08-19 애브비 인코포레이티드 항-ｖｅｇｆ／ｄｌｌ4 이원 가변 도메인 면역글로불린 및 이의 용도
US20140213771A1 (en) * 2012-12-28 2014-07-31 Abbvie, Inc. Multi-specific binding proteins
JP2016506720A (ja) 2013-01-21 2016-03-07 アッヴィ・インコーポレイテッド 炎症性疾患のための抗ｔｎｆ及び抗ｉｌ１７併用治療薬バイオマーカー
WO2014122613A1 (en) * 2013-02-08 2014-08-14 Novartis Ag Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders
TW201444867A (zh) * 2013-03-08 2014-12-01 Lilly Co Eli 抗ｔｎｆ－抗ｉｌ－１７雙特異性抗體
MX2015013166A (es) 2013-03-15 2015-12-11 Abbvie Inc Proteinas de union especificas duales dirigidas contra il-1 beta y/o il-17.
WO2014161570A1 (en) 2013-04-03 2014-10-09 Roche Glycart Ag Antibodies against human il17 and uses thereof
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
CN115715797A (zh) * 2013-04-17 2023-02-28 建新公司 用于治疗和预防黄斑变性的组合物和方法
BR112015027373A2 (pt) 2013-05-03 2017-08-29 Fujifilm Diosynth Biotechnologies Uk Ltd Processo de expressão
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
EP3027649B1 (en) * 2013-08-01 2020-04-01 F.Hoffmann-La Roche Ag Tnfa-il-17 bispecific antibodies
BR112016003196A8 (pt) 2013-08-19 2020-02-04 Hoffmann La Roche método para separar anticorpos biespecíficos
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
WO2015061397A1 (en) 2013-10-22 2015-04-30 The General Hostpital Corporation Cromolyn derivatives and related methods of imaging and treatment
MX2016006101A (es) * 2013-11-18 2016-07-21 Shanghai Hengrui Pharm Co Ltd Agente ligante de la il-17a y usos del mismo.
US9959384B2 (en) 2013-12-10 2018-05-01 Bioniz, Llc Methods of developing selective peptide antagonists
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
CA2938996A1 (en) 2014-02-10 2015-08-13 Patara Pharma, LLC Methods for the treatment of lung diseases with mast cell stabilizers
PL3104853T3 (pl) 2014-02-10 2020-05-18 Respivant Sciences Gmbh Leczenie stabilizatorami komórek tucznych zaburzeń ogólnoustrojowych
US20150291689A1 (en) * 2014-03-09 2015-10-15 Abbvie, Inc. Compositions and Methods for Treating Rheumatoid Arthritis
CA2943943C (en) 2014-04-07 2023-01-10 Chugai Seiyaku Kabushiki Kaisha Immunoactivating antigen-binding molecule
CN104311670B (zh) * 2014-04-23 2017-05-17 哈尔滨博翱生物医药技术开发有限公司 针对IL‑17和TNFα的融合多肽及其应用
BR112016026299A2 (pt) 2014-05-13 2018-02-20 Chugai Seiyaku Kabushiki Kaisha molécula de ligação ao antígeno redirecionado à célula t para células tendo função de imunossupressão
US20160000936A1 (en) 2014-06-10 2016-01-07 Abbvie Inc. Biomarkers for inflammatory disease and methods of using same
US20160002326A1 (en) 2014-06-10 2016-01-07 Abbvie Inc. Compositions and methods for treating rheumatoid arthritis
WO2016040880A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies of alk inhibitors
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
RU2017115670A (ru) * 2014-10-10 2018-11-15 Аблинкс Н.В. Лечение инфекции рсв
JP2017537891A (ja) * 2014-10-31 2017-12-21 ジェネンテック， インコーポレイテッド 抗ｉｌ−１７ａ及びｉｌ−１７ｆ交差反応性抗体変異体、ならびにそれらを含む組成物、それらを作製する方法、及び使用する方法
JP7231326B2 (ja) 2014-11-10 2023-03-01 ジェネンテック， インコーポレイテッド Ｉｌ－３３媒介性障害のための治療及び診断方法
MX2017006094A (es) 2014-11-10 2017-07-19 Genentech Inc Anticuerpos anti-interleucina-33 y sus usos.
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
KR102523805B1 (ko) 2014-12-23 2023-04-20 4디 파마 리서치 리미티드 면역 조정
EP3400953A1 (en) 2014-12-23 2018-11-14 4D Pharma Research Limited Pirin polypeptide and immune modulation
KR20170116023A (ko) * 2015-01-12 2017-10-18 애피바디 에이비 Il-17a-결합 폴리펩티드
GB201500463D0 (en) * 2015-01-12 2015-02-25 Cresendo Biolog Ltd Therapeutic molecules
US20160244520A1 (en) 2015-01-24 2016-08-25 Abbvie Inc. Compositions and methods for treating psoriatic arthritis
WO2016160976A2 (en) 2015-03-30 2016-10-06 Abbvie Inc. Monovalent tnf binding proteins
MX2017014908A (es) 2015-05-21 2018-08-15 Harpoon Therapeutics Inc Proteinas de union triespecificas y metodos de uso.
MX2017014953A (es) 2015-05-22 2018-08-15 Chong Kun Dang Pharmaceutical Corp Compuestos derivados de alquilos heterociclicos como inhibidores de histona desacetilasa selectivos y composiciones farmaceuticas que los comprenden.
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
EA038405B1 (ru) 2015-06-15 2021-08-24 4Д Фарма Рисёрч Лимитед ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ШТАММЫ БАКТЕРИИ Bifidobacterium breve, ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ЗАБОЛЕВАНИЯ ИЛИ ПАТОЛОГИЧЕСКОГО СОСТОЯНИЯ, ОПОСРЕДОВАННОГО IL-17 ИЛИ Th17
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
EA201890050A1 (ru) 2015-06-15 2018-06-29 4Д Фарма Рисёрч Лимитед Композиции, содержащие бактериальные штаммы
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
EA201890048A1 (ru) 2015-06-15 2018-06-29 4Д Фарма Рисёрч Лимитед Композиции, содержащие бактериальные штаммы
PE20221007A1 (es) 2015-06-24 2022-06-15 Hoffmann La Roche Anticuerpos anti-receptor de transferrina con afinidad disenada
US10238625B2 (en) 2015-08-07 2019-03-26 Respivant Sciences Gmbh Methods for the treatment of mast cell related disorders with mast cell stabilizers
US10265296B2 (en) 2015-08-07 2019-04-23 Respivant Sciences Gmbh Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
CA2997801A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
KR102654684B1 (ko) 2015-10-09 2024-04-04 바이오니즈 테라퓨틱스, 아이엔씨. 감마-ｃ-사이토카인 활성의 조정
PT3370770T (pt) 2015-11-03 2021-02-22 Janssen Biotech Inc Formulações subcutâneas de anticorpos anti-cd38 e suas utilizações
US10988543B2 (en) 2015-11-11 2021-04-27 Opi Vi—Ip Holdco Llc Humanized anti-tumor necrosis factor alpha receptor 2 (anti-TNFR2) antibodies and methods of use thereof to elicit an immune response against a tumor
EP3378487B1 (en) 2015-11-18 2022-03-16 Chugai Seiyaku Kabushiki Kaisha Combination therapy using t cell redirection antigen binding molecule against cell having immunosuppressing function
JP6925278B2 (ja) 2015-11-18 2021-08-25 中外製薬株式会社 液性免疫応答の増強方法
NZ742787A (en) 2015-11-20 2020-02-28 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
EP3380095B1 (en) * 2015-11-23 2022-01-05 The General Hospital Corporation Compositions and methods for treating ischemic stroke
US11649262B2 (en) 2015-12-28 2023-05-16 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of Fc region-containing polypeptide
MA45280B1 (fr) 2016-03-02 2021-08-31 Eisai R&D Man Co Ltd Conjugués anticorps-médicament à base d'éribuline et leurs procédés d'utilisation
DK3313423T3 (da) 2016-03-04 2019-05-20 4D Pharma Plc Sammensætninger omfattende bakterielle blautia-stammer til behandling af visceral hypersensitivitet
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
BR112018068363A2 (pt) 2016-03-14 2019-01-15 Chugai Pharmaceutical Co Ltd fármaco terapêutico indutor de dano celular para uso em terapia de câncer
RU2680011C2 (ru) 2016-04-29 2019-02-14 Закрытое Акционерное Общество "Биокад" Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2017189959A1 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
WO2017201488A1 (en) 2016-05-20 2017-11-23 Harpoon Therapeutics, Inc. Single domain serum albumin binding protein
CN107488227A (zh) * 2016-06-12 2017-12-19 三生国健药业（上海）股份有限公司 抗人白细胞介素‑17a单克隆抗体、其制备方法和应用
TW201821093A (zh) 2016-07-13 2018-06-16 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
JP2019528320A (ja) 2016-08-31 2019-10-10 レシュピファント サイエンシス ゲゼルシャフト ミット ベシュレンクター ハフトゥングＲｅｓｐｉｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ 特発性肺線維症による慢性咳の治療のためのクロモリン組成物
KR20190044647A (ko) 2016-08-31 2019-04-30 더 제너럴 하스피탈 코포레이션 신경변성 질환과 관련된 신경-염증에서 대식세포/미세아교세포
MY185578A (en) 2016-09-14 2021-05-22 Beijing hanmi pharm co ltd Antibody specifically binding to il-17a and functional fragment thereof
CN109803724A (zh) 2016-10-07 2019-05-24 瑞思皮万特科学有限责任公司 用于治疗肺纤维化的色甘酸组合物
JP2019537600A (ja) 2016-11-02 2019-12-26 ナノプロティアジェン， リミテッド ポリマーナノ粒子
WO2018098354A1 (en) 2016-11-23 2018-05-31 Harpoon Therapeutics, Inc. Prostate specific membrane antigen binding protein
US10844134B2 (en) 2016-11-23 2020-11-24 Harpoon Therapeutics, Inc. PSMA targeting trispecific proteins and methods of use
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
JP7129912B2 (ja) * 2016-12-07 2022-09-02 株式会社ステリック再生医科学研究所 慢性疾患の治療及び予防用医薬組成物
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
US11535668B2 (en) 2017-02-28 2022-12-27 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
CN110891974B (zh) 2017-05-12 2021-08-06 哈普恩治疗公司 间皮素结合蛋白质
US10730954B2 (en) 2017-05-12 2020-08-04 Harpoon Therapeutics, Inc. MSLN targeting trispecific proteins and methods of use
MA48940A (fr) 2017-05-22 2020-04-08 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA41708A (fr) 2017-05-24 2020-04-08 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
HUE052319T2 (hu) 2017-06-14 2021-04-28 4D Pharma Res Ltd Baktériumtörzseket tartalmazó készítmények
WO2018229236A2 (en) 2017-06-14 2018-12-20 4D Pharma Research Limited Compositions comprising bacterial strains
KR20210070232A (ko) 2017-07-20 2021-06-14 아즈테라피즈 인코포레이티드 크로몰린 나트륨 및 이부프로펜의 분말화된 제형
CN108359011B (zh) * 2017-07-21 2019-06-25 华博生物医药技术（上海）有限公司 靶向于白介素17a的抗体、其制备方法和应用
EA202090817A1 (ru) 2017-10-13 2020-09-08 Харпун Терапьютикс, Инк. Триспецифические белки и способы их применения
CA3078799A1 (en) 2017-10-13 2019-04-18 Harpoon Therapeutics, Inc. B cell maturation antigen binding proteins
US10285998B1 (en) 2018-04-04 2019-05-14 The Menopause Method, Inc. Composition and method to aid in hormone replacement therapy
CN113038944A (zh) 2018-07-02 2021-06-25 通用医疗公司 色甘酸钠和α-乳糖的粉末化制剂
WO2020061482A1 (en) * 2018-09-21 2020-03-26 Harpoon Therapeutics, Inc. Egfr binding proteins and methods of use
CN113286817A (zh) 2018-09-25 2021-08-20 哈普恩治疗公司 Dll3结合蛋白及使用方法
GB201820006D0 (en) * 2018-12-07 2019-01-23 Lifearc Humanised anti-IL17BR antibody
US11352421B2 (en) * 2018-12-11 2022-06-07 Rush University Medical Center Treatment for adverse immune reaction to metal implant debris
KR20210122243A (ko) * 2019-01-31 2021-10-08 누맙 세러퓨틱스 아게 ＴＮＦα 및 ＩＬ-17Ａ에 대한 특이성을 가지는 다중 특이적 항체, ＩＬ-17Ａ를 표적화하는 항체, 그리고 이의 사용 방법
EP3689907A1 (en) 2019-01-31 2020-08-05 Numab Therapeutics AG Antibodies targeting il-17a and methods of use thereof
CA3129901A1 (en) 2019-02-18 2020-08-27 Eli Lilly And Company Therapeutic antibody formulation
CA3136992A1 (en) * 2019-05-24 2020-12-03 Proviva Therapeutics (Hong Kong) Limited Il-2 compositions and methods of use thereof
EP3997115A4 (en) * 2019-07-12 2023-11-22 Proviva Therapeutics (Hong Kong) Limited IL-2 COMPOSITIONS AND METHODS OF USE THEREOF
WO2021055376A1 (en) * 2019-09-16 2021-03-25 Dice Alpha, Inc. Il-17a modulators and uses thereof
JP2022551603A (ja) 2019-10-03 2022-12-12 エータイアー ファーマ， インコーポレイテッド 抗ｎｒｐ２抗体を含む組成物および方法
AU2021208482A1 (en) 2020-01-13 2022-07-21 Denali Therapeutics Inc. Anti-TREM2 antibodies and methods of use thereof
BR112022016550A2 (pt) 2020-02-21 2022-11-16 Harpoon Therapeutics Inc Proteínas de ligação a flt3 e métodos de uso
IL296256A (en) 2020-03-13 2022-11-01 Genentech Inc Antibodies against interleukin-33 and uses thereof
US11197910B1 (en) 2020-08-19 2021-12-14 Vitruviae LLC Fusion proteins for the diagnosis, prophylaxis and treatment of infectious diseases
US11124568B1 (en) * 2020-08-19 2021-09-21 Vitruviae LLC CD3/CD25 antibodies for neuro-immune diseases
CN112538526B (zh) * 2020-12-10 2023-03-17 中山大学附属第五医院 Slamf7重组蛋白在制备治疗脓毒症药物中的应用
AU2022375785A1 (en) * 2021-10-27 2024-04-11 Atyr Pharma, Inc. COMPOSITIONS AND METHODS COMPRISING ANTI-NRP2a ANTIBODIES
CN114283896B (zh) * 2021-12-23 2022-11-18 江南大学 一种监测酶促反应过程中组分变化模型的建模方法
CN117106083A (zh) * 2022-03-25 2023-11-24 南京融捷康生物科技有限公司 一种抗il-17a的单域抗体及其用途
CN117843777A (zh) * 2023-12-21 2024-04-09 北京贝来药业有限公司 用于炎性疾病治疗的新型纳米抗体及其产品和方法

Family Cites Families (185)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
ATE37983T1 (de) * 1982-04-22 1988-11-15 Ici Plc Mittel mit verzoegerter freigabe.
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4753894A (en) 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US5807715A (en) * 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
DE3590766T (es) 1985-03-30 1987-04-23
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3750503T2 (de) 1986-10-22 1995-02-09 Abbott Lab Chemilumineszierende Acridinium- und Phenantridiniumsalze.
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5006309A (en) 1988-04-22 1991-04-09 Abbott Laboratories Immunoassay device with liquid transfer between wells by washing
US5089424A (en) 1988-06-14 1992-02-18 Abbott Laboratories Method and apparatus for heterogeneous chemiluminescence assay
EP1892296A1 (en) 1988-09-02 2008-02-27 Dyax Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5241070A (en) * 1988-09-26 1993-08-31 Ciba Corning Diagnostics Corp. Nucleophilic polysubstituted aryl acridinium esters and uses thereof
SE462454B (sv) 1988-11-10 1990-06-25 Pharmacia Ab Maetyta foer anvaendning i biosensorer
AU634186B2 (en) 1988-11-11 1993-02-18 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5063081A (en) 1988-11-14 1991-11-05 I-Stat Corporation Method of manufacturing a plurality of uniform microfabricated sensing devices having an immobilized ligand receptor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2057923A1 (en) 1989-05-16 1990-11-17 William D. Huse Co-expression of heteromeric receptors
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
CA2016841C (en) 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
WO1991005548A1 (en) 1989-10-10 1991-05-02 Pitman-Moore, Inc. Sustained release composition for macromolecular proteins
CA2071867A1 (en) 1989-11-06 1991-05-07 Edith Mathiowitz Method for producing protein microspheres
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5780225A (en) * 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
US6075181A (en) * 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0542810A1 (en) 1990-08-02 1993-05-26 B.R. Centre Limited Methods for the production of proteins with a desired function
CA2048302A1 (en) 1990-08-15 1992-02-16 Victoria P. Meucci Solubilization reagent for biological test samples
US5135875A (en) * 1990-08-15 1992-08-04 Abbott Laboratories Protein precipitation reagent
WO1992003461A1 (en) 1990-08-24 1992-03-05 Ixsys, Inc. Methods of synthesizing oligonucleotides with random codons
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
DK0564531T3 (da) * 1990-12-03 1998-09-28 Genentech Inc Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
NZ241119A (en) 1990-12-20 1993-06-25 Ixsys Inc Manipulating nucleic acid to optimize the binding characteristics of the encoded binding protein
AU1545692A (en) 1991-03-01 1992-10-06 Protein Engineering Corporation Process for the development of binding mini-proteins
DE69233153T2 (de) 1991-03-06 2004-05-27 Merck Patent Gmbh Humanisierte monoklonale antikörper
ATE269401T1 (de) 1991-04-10 2004-07-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
EP0583356B1 (en) 1991-05-01 2002-07-31 Henry M. Jackson Foundation For The Advancement Of Military Medicine A method for treating infectious respiratory diseases
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
CA2069530A1 (en) 1991-06-03 1992-12-04 Cass J. Grandone Reagent pack for immunoassays
JPH07503124A (ja) 1991-06-14 1995-04-06 ゾーマ・コーポレーション 微生物によって生産される抗体断片とそれらの複合体
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
DK0605522T3 (da) 1991-09-23 2000-01-17 Medical Res Council Fremgangsmåde til fremstilling af humaniserede antistoffer
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
CA2507749C (en) 1991-12-13 2010-08-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5733743A (en) * 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0649533B1 (en) * 1992-03-30 2000-05-10 Abbott Laboratories Reagents and methods for the detection and quantification of thyroxine in fluid samples
US5352803A (en) * 1992-03-30 1994-10-04 Abbott Laboratories 5(6)-methyl substituted fluorescein derivatives
JPH07509137A (ja) 1992-07-24 1995-10-12 セル　ジェネシス，インク． 異種抗体の生産
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
WO1994018219A1 (en) 1993-02-02 1994-08-18 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
US5565352A (en) * 1993-11-24 1996-10-15 Arch Development Corporation Deubiquitinating enzyme: compositions and methods
JPH09506262A (ja) 1993-12-08 1997-06-24 ジェンザイム・コーポレイション 特異的抗体の製造方法
GB9401182D0 (en) 1994-01-21 1994-03-16 Inst Of Cancer The Research Antibodies to EGF receptor and their antitumour effect
AU1736495A (en) 1994-01-31 1995-08-15 Trustees Of Boston University Polyclonal antibody libraries
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
DE69534530T2 (de) * 1994-08-12 2006-07-06 Immunomedics, Inc. Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper
US7635479B2 (en) * 2000-03-29 2009-12-22 The Trustees Of The University Of Pennsylvania Composition and methods for enhancing immunogenecity of antigens
WO1996020698A2 (en) 1995-01-05 1996-07-11 The Board Of Regents Acting For And On Behalf Of The University Of Michigan Surface-modified nanoparticles and method of making and using same
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US5641870A (en) * 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
JPH11503914A (ja) 1995-04-21 1999-04-06 セル ジェネシス，インコーポレイテッド 大ゲノムｄｎａ欠失の生成
EP1709970A1 (en) 1995-04-27 2006-10-11 Abgenix, Inc. Human antibodies against EGFR, derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2222231A1 (en) 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
US6127977A (en) 1996-11-08 2000-10-03 Cohen; Nathan Microstrip patch antenna with fractal structure
WO1997007788A2 (en) 1995-08-31 1997-03-06 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US6331431B1 (en) 1995-11-28 2001-12-18 Ixsys, Inc. Vacuum device and method for isolating periplasmic fraction from cells
JP2978435B2 (ja) * 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
DE69721548T2 (de) * 1996-02-09 2004-04-01 Abbott Laboratories(Bermuda)Ltd. HUMANE ANTIKÖRPER WELCHE AN HUMANEN TNFalpha BINDEN
US5985320A (en) 1996-03-04 1999-11-16 The Penn State Research Foundation Materials and methods for enhancing cellular internalization
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5855913A (en) * 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US6699658B1 (en) * 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
ATE549918T1 (de) 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
CA2277801C (en) 1997-01-16 2002-10-15 Massachusetts Institute Of Technology Preparation of particles for inhalation
ATE529509T1 (de) 1997-01-21 2011-11-15 Gen Hospital Corp Selektion von proteinen unter verwendung von rna- protein-fusionen
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
NZ516848A (en) 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
WO1999006834A2 (en) 1997-08-04 1999-02-11 Ixsys, Incorporated Methods for identifying ligand specific binding molecules
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
CA2322749A1 (en) 1998-03-03 1999-09-10 Abgenix, Inc. Cd147 binding molecules as therapeutics
WO1999051773A1 (en) 1998-04-03 1999-10-14 Phylos, Inc. Addressable protein arrays
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
AU747231B2 (en) 1998-06-24 2002-05-09 Alkermes, Inc. Large porous particles emitted from an inhaler
US6406921B1 (en) 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
WO2000034337A1 (en) 1998-12-10 2000-06-15 Tsukuba Research Laboratory, Toagosei Co., Ltd. Humanized monoclonal antibodies against vascular endothelial cell growth factor
IL143797A0 (en) 1998-12-23 2002-04-21 Pfizer Human monoclonal antibodies to cytotoxic t lymphocyte antigen 4
IL144600A0 (en) * 1999-02-12 2002-05-23 Genetics Inst Humanized immunoglobulin reactive with b7 molecules and methods of treatment therewith
AU4025300A (en) 1999-03-24 2000-10-09 Packard Bioscience Company Continuous porous matrix arrays
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
JP4841038B2 (ja) 1999-03-25 2011-12-21 アボット ゲーエムベーハー ウント カンパニー カーゲー ヒトｉｌ−１２に結合するヒト抗体およびその産生法
DK2275540T3 (en) 1999-04-09 2016-05-09 Kyowa Hakko Kirin Co Ltd Method for controlling the activity of immunologically functional molecule.
US7129332B2 (en) 2000-02-25 2006-10-31 The United States Of America As Represented By The Department Of Health And Human Services Anti-EGFRvIII scFvs with improved cytotoxicity and yield, immunotoxins based thereon, and methods of use thereof
WO2001070998A1 (en) 2000-03-20 2001-09-27 Dsm N.V. Talaromyces emersonii beta-glucanases
CN101289511A (zh) 2000-04-11 2008-10-22 杰南技术公司 多价抗体及其应用
CA2407956A1 (en) 2000-05-03 2001-11-08 Amgen Inc. Modified peptides as therapeutic agents
DE60116753T2 (de) 2000-05-19 2006-09-14 Scancell Ltd. Humanisierte antikörper gegen den epidermalen wachstumsfaktorrezeptor
ATE309385T1 (de) 2000-06-28 2005-11-15 Glycofi Inc Verfahren für die herstellung modifizierter glykoproteine
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
EP2899210A3 (en) 2000-06-29 2015-11-18 Abbvie Inc. Dual specificity antibodies and methods of making and using
CA2433353C (en) 2000-12-28 2017-03-21 Altus Biologics, Inc. Crystals of whole antibodies and fragments thereof and methods for making and using them
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
IL159225A0 (en) * 2001-06-13 2004-06-01 Genmab As Human monoclonal antibodies to epidermal growth factor receptor (egfr)
EP1432444A4 (en) 2001-08-17 2005-11-02 Lilly Co Eli ANTI-BETA ANTIBODIES
ATE434040T1 (de) 2001-10-01 2009-07-15 Dyax Corp Mehrkettige eukaryontische display-vektoren und deren verwendungen
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
EP1443961B1 (en) 2001-10-25 2009-05-06 Genentech, Inc. Glycoprotein compositions
AU2002346373A1 (en) 2001-11-09 2003-05-19 Idec Pharmaceuticals Corporation Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
WO2003043321A1 (en) 2001-11-10 2003-05-22 Thomson Licensing S.A. Video recording system and method for a plurality of individual users and categories of users
DE10156482A1 (de) 2001-11-12 2003-05-28 Gundram Jung Bispezifisches Antikörper-Molekül
US7419821B2 (en) * 2002-03-05 2008-09-02 I-Stat Corporation Apparatus and methods for analyte measurement and immunoassay
PT1523496E (pt) 2002-07-18 2011-09-29 Merus B V Produção de misturas de anticorpos de forma recombinante
US20040018577A1 (en) 2002-07-29 2004-01-29 Emerson Campbell John Lewis Multiple hybrid immunoassay
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
PL2163643T3 (pl) 2003-03-05 2015-06-30 Halozyme Inc Rozpuszczalna glikoproteina o aktywności hialuronidazy (sHASEGP), sposób jej wytwarzania, zastosowania oraz zawierające ją kompozycje farmaceutyczne
JP2007525195A (ja) * 2003-06-02 2007-09-06 アレクシオン ファーマシューティカルズ， インコーポレイテッド ヒト慢性リンパ球性白血病に関連する細胞表面タンパク質
CA2537055A1 (en) 2003-08-22 2005-04-21 Medimmune, Inc. Humanization of antibodies
US7723099B2 (en) * 2003-09-10 2010-05-25 Abbott Point Of Care Inc. Immunoassay device with immuno-reference electrode
US7682833B2 (en) 2003-09-10 2010-03-23 Abbott Point Of Care Inc. Immunoassay device with improved sample closure
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
WO2005111082A1 (en) 2004-04-30 2005-11-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-tfr antibody.
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0425569D0 (en) * 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
JP2008524247A (ja) 2004-12-15 2008-07-10 エラン ファーマ インターナショナル リミテッド 認知の改善における使用のためのアミロイドβ抗体
RU2007129263A (ru) 2005-02-14 2009-03-20 Вайет (Us) Антитела к интерлейкину-17f и другие антагонисты опосредуемой il-17f передачи сигналов и их применение
EP2295466A3 (en) 2005-04-25 2011-08-17 Pfizer Inc. Antibodies to myostatin
BRPI0611714A2 (pt) * 2005-06-30 2009-01-13 Abbott Lab proteÍnas de ligaÇço a il-12/p40
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2495257A3 (en) * 2005-08-19 2012-10-17 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
LT2481753T (lt) * 2005-12-13 2018-05-25 Eli Lilly And Company Anti-il-17 antikūnai
GB0600488D0 (en) 2006-01-11 2006-02-22 Glaxo Group Ltd Immunoglobulins
AU2007235199B8 (en) * 2006-01-31 2010-10-28 Novartis Ag IL-17 antagonistic antibodies for treating cancer
DE602007006429D1 (de) * 2006-02-10 2010-06-24 Zymogenetics Inc Lösliches il-17rcx4 und verfahren zu dessen anwendung bei entzündungen
KR101317235B1 (ko) 2006-04-21 2013-10-15 조마 테크놀로지 리미티드 길항제 항-ｃｄ40 항체 제약 조성물
TW200815469A (en) 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
GB0612928D0 (en) 2006-06-29 2006-08-09 Ucb Sa Biological products
US7883855B2 (en) 2006-07-21 2011-02-08 Abbott Laboratories Immunosuppressant drug extraction reagent for immunoassays
AR063683A1 (es) 2006-08-11 2009-02-11 Schering Corp Anticuerpos para il-17a
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
US20100303777A1 (en) 2006-12-14 2010-12-02 Actogenix N.V. Delivery of binding molecules to induce immunomodulation
JP5319549B2 (ja) 2006-12-29 2013-10-16 アボット・ラボラトリーズ 溶液内捕捉イムノアッセイで使用する非変性細胞溶解試薬
DE602008004296D1 (de) * 2007-02-14 2011-02-17 Vaccinex Inc Humanisierte anti-cd100-antikörper
CA2679266A1 (en) 2007-02-27 2008-09-04 Forerunner Pharma Research Co., Ltd. Pharmaceutical composition comprising anti-grp78 antibody as active ingredient
US7906293B2 (en) 2007-04-09 2011-03-15 Abbott Laboratories Acridinium phenyl esters useful in the analysis of biological
JP5646457B2 (ja) 2008-04-29 2014-12-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
EP3002299A1 (en) 2008-06-03 2016-04-06 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
KR20110016959A (ko) 2008-06-03 2011-02-18 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
US8404445B2 (en) 2008-09-30 2013-03-26 Abbvie Inc. Antibody libraries
AU2009334505B2 (en) * 2008-12-31 2013-05-09 Abbott Point Of Care Inc. Method and device for immunoassay using nucleotide conjugates
RU2015132478A (ru) 2009-03-05 2015-12-10 Эббви Инк. Связывающие il-17 белки
MY160445A (en) 2010-08-03 2017-03-15 Abbvie Inc Dual Variable Domain Immunoglobulins And Uses Thereof

Also Published As

Publication number Publication date
CA2752648A1 (en) 2010-09-10
BRPI1013688A2 (pt) 2016-10-11
EP2810652A2 (en) 2014-12-10
PE20160653A1 (es) 2016-07-24
EP2772269A2 (en) 2014-09-03
US9481735B2 (en) 2016-11-01
US20140348856A1 (en) 2014-11-27
UY32477A (es) 2010-06-30
ECSP11011297A (es) 2011-10-31
PE20160651A1 (es) 2016-07-24
CN102781470B (zh) 2016-01-20
HK1200320A1 (en) 2015-08-07
CO6410314A2 (es) 2012-03-30
EP2403531A4 (en) 2013-02-27
TW201043241A (en) 2010-12-16
PH12015500093A1 (en) 2019-02-11
EP3235509A1 (en) 2017-10-25
US8779101B2 (en) 2014-07-15
NZ611324A (en) 2015-02-27
DOP2011000274A (es) 2011-10-31
PE20121094A1 (es) 2012-09-13
AU2010221166A1 (en) 2011-09-08
WO2010102251A3 (en) 2010-11-25
JP2012519708A (ja) 2012-08-30
KR101579771B1 (ko) 2015-12-28
JP2015131809A (ja) 2015-07-23
EP2810652A3 (en) 2015-03-11
US20140356909A1 (en) 2014-12-04
EP2403531A2 (en) 2012-01-11
JP5836807B2 (ja) 2015-12-24
IL214851A0 (en) 2011-11-30
CN102781470A (zh) 2012-11-14
CL2013003640A1 (es) 2014-07-25
TW201613969A (en) 2016-04-16
US9663587B2 (en) 2017-05-30
MX2011009362A (es) 2011-09-26
EP2772269A3 (en) 2015-01-14
CR20110470A (es) 2011-12-08
RU2011140335A (ru) 2013-04-10
JP2016047820A (ja) 2016-04-07
SG10201402960SA (en) 2014-08-28
US20100266531A1 (en) 2010-10-21
RU2015132478A (ru) 2015-12-10
SG173705A1 (en) 2011-09-29
KR20110128909A (ko) 2011-11-30
US20140017246A1 (en) 2014-01-16
US9481736B2 (en) 2016-11-01
TWI541021B (zh) 2016-07-11
US20140335564A1 (en) 2014-11-13
HK1202806A1 (en) 2015-10-09
WO2010102251A2 (en) 2010-09-10
CL2011002129A1 (es) 2012-04-20
US20140343267A1 (en) 2014-11-20
US20140348834A1 (en) 2014-11-27
JP5819013B2 (ja) 2015-11-18
US8835610B2 (en) 2014-09-16
BRPI1013688A8 (pt) 2017-02-14
CN105254758A (zh) 2016-01-20
NZ594514A (en) 2013-06-28
KR20150018646A (ko) 2015-02-23

Similar Documents

Publication Publication Date Title
AR075798A1 (es) Proteinas de union a il-17 (interleuquina 17)
IL261585A (en) Antigen-binding human proteins that bind beta-klotho, fgf receptors and their complexes
AR078778A1 (es) Proteinas de union a antigenos de il-23
AR066794A1 (es) Proteina de union que comprende un dominio de union a antigeno que se une al globulomero beta amiloide (20-42), anticuerpos, molecula de acido nucleico que la codifica vector, celula huesped, metodo para su produccion, usos, composicion farmaceutia y metodo de diagnostico
AR081556A1 (es) Proteinas de union al antigeno humanizadas
CL2008003004A1 (es) Anticuerpo anti-esclerostina o su porción de enlace de antígeno; polinucleotido que lo codifica; vector; célula; proceso de producción; composición farmacéutica que lo comprende; método para identificar células y su uso para tratar trastornos óseos.
JP2020536109A5 (es)
NZ603972A (en) Anti-fgfr2 antibodies
PE20140133A1 (es) Nuevas proteinas de union a antigenos
RU2011129204A (ru) Антитела против ангиопоэтина-2 человека
EA201391761A1 (ru) Анти-альфа-синуклеинсвязывающие молекулы
EP2471817A3 (en) Humanized antibody molecules specific for IL-31
PE20090518A1 (es) Proteinas enlazantes de antigenos que enlazan al receptor de la interleucina 18 (il-18)
PE20120622A1 (es) Anticuerpos anti-vegf y sus usos
EA032189B9 (ru) Изолированные человеческие моноклональные антитела против ингибитора пути тканевого фактора (tfpi) и фармацевтическая композиция, содержащая их
AR080243A1 (es) Composiciones y metodos para el diagnostico y tratamiento de tumores
JP2014512809A5 (es)
NZ628792A (en) Il-1 binding proteins
UA109633C2 (uk) Антитіло людини проти тканинного фактора
JP2016512214A5 (es)
AR072985A1 (es) Tratamiento para una enfermedad autoinmune o trastorno inflamatorio, procedimiento, anticuerpo, proteina de union
CO6231009A2 (es) Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes
CO6430469A2 (es) Anticuerpos humanizados que se unen a cd19 y sus usos
PE20061324A1 (es) Anticuerpos anti-il-6, composiciones, metodos y usos
BR112012021329A2 (pt) anticorpo monoclonal anti-tnf-<244> completamente humano, método de preparação e uso do mesmo.

Legal Events

Date Code Title Description
FB Suspension of granting procedure